Update (9:40 a.m.): Updated with Wednesday market open information.
The stock was flat at 9:38 a.m. on Wednesday.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.